Welcome to the CCO Site

Thank you for your interest in CCO content. As a guest, please complete the following information fields. These data help ensure our continued delivery of impactful education. 

Become a member (or login)? Member benefits include accreditation certificates, downloadable slides, and decision support tools.

Submit

COVID-19: Which Drug, When, and Why? Anti-inflammatory Agents and Immunomodulators

In which patients with COVID-19 should we use anti-inflammatory agents and immunomodulators? Hear expert insights on the timing and role of convalescent plasma, corticosteroids, IL-6 inhibitors, and JAK inhibitors in the treatment of COVID-19.
Vikramjit Mukherjee, MD
Released: April 7, 2022

Anti-inflammatory agents and immunomodulators are key components to treating patients who are severely or critically ill due to a COVID-19 infection.

In this episode, Vikramjit Mukherjee, MD, discusses the role and timing of these treatment options, including:

  • High-titer convalescent plasma
  • Corticosteroids
  • Interleukin-6 inhibitors (eg, tocilizumab)
  • Janus kinase inhibitors (eg, baricitinib)

Acknowledgements

Provided by Clinical Care Options, LLC

Contact Clinical Care Options

For customer support please email: customersupport@cealliance.com

Mailing Address
Clinical Care Options, LLC
12001 Sunrise Valley Drive
Suite 300
Reston, VA 20191

This program is supported by an educational grant from
Gilead Sciences, Inc.

Information on this Educational Activity

Faculty

Vikramjit Mukherjee, MD

Assistant Professor of Medicine
Division of Pulmonary, Critical Care, & Sleep Medicine
New York University School of Medicine
Director, Medical Intensive Care Unit
Bellevue Hospital
New York, New York

Vikramjit Mukherjee, MD, has no relevant conflicts of interest to report.

Program Medium

This program has been made available online.

Related Content

Prof. Sharon R. Lewin: expert insights on remdesivir for nonhospitalized adult and pediatric patients with COVID-19, from Clinical Care Options (CCO)

Sharon R. Lewin, AO, FRACP, PhD, FAHMS Released: June 7, 2022

Prof. Sharon R. Lewin discusses ivermectin and the evolution of monoclonal antibody treatments during omicron, from Clinical Care Options (CCO)

Sharon R. Lewin, AO, FRACP, PhD, FAHMS Released: June 7, 2022

Megan Coffee, MD, PhD, discusses the newest data on SARS-CoV-2 diagnostics from CROI 2022 and elsewhere, from Clinical Care Options (CCO)

Megan Coffee, MD, PhD (DPhil) Released: June 2, 2022

Frequently asked questions and answers: evolving data on COVID-19 epidemiology, prevention, and treatment, from Clinical Care Options (CCO)

Arthur Kim, MD Sharon R. Lewin, AO, FRACP, PhD, FAHMS Renslow Sherer, MD Released: June 1, 2022

Leaving the CCO site

You are now leaving the CCO site. The new destination site may have different terms of use and privacy policy.

Continue

Cookie Settings